Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

App therapy tackles mental health in opioid treatment

NCT ID NCT05047627

Symptom relief Sponsor: Trustees of Dartmouth College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a smartphone app designed to reduce anxiety and depression in people already receiving medication for opioid use disorder. 63 adults were randomly assigned to use the app for four weeks or to continue their usual care. The goal was to see if the app was feasible and acceptable, and to get early data on whether it could improve mental health and reduce opioid cravings and use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Smartphone-based digital intervention (cognitive-behavioral therapy app)
What this could lead to
If it works, this could provide a low-cost, scalable way to treat anxiety and depression in people receiving medication for opioid use disorder, potentially improving overall outcomes.
What could go wrong
This was a small, early feasibility study with only 63 participants and no control for the app's specific effects. The intervention was still being developed, so results may not be generalizable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

63 people

The number who actually took part.

Started

Sep 2021

Finished

Mar 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (age 18 or older) * fluent in English * able to provide informed consent * meet current criteria for OUD (as defined by a Rapid Opioid Dependence Screen) * are receiving methadone, buprenorphine, and/or naltrexone for OUD * meet current criteria for an anxiety and/or depressive disorder (based on the Patient Health Questionnaire and the Generalized Anxiety Disorder Questionnaire). Exclusion Criteria: * active suicidality * psychosis * bipolar disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder depressive disorder opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety disorders Depressive disorder Opioid use disorder

Contacts and locations

Locations

  • Center For Technology and Behavioral Health

    Lebanon, New Hampshire, 03766, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.